Mary McManmon, MD
Family Medicine · Elkhart, INNPI 1255363172
Payments from drug & device makers
Across 144 payments — averaging $19.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$401
- GSK$308
- Mylan Specialty L.p.$251
- Baxter Healthcare$241
- Lilly USA, LLC$213
- Merck$183
- plus $1K from 16 others
What the payments were for
- Food & beverage$2,46289%
- Other$30511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 20 | $401 |
| GSK | 15 | $308 |
| Mylan Specialty L.p. | 12 | $251 |
| Baxter Healthcare | 2 | $241 |
| Lilly USA, LLC | 14 | $213 |
| Merck | 12 | $183 |
| Boehringer Ingelheim | 11 | $182 |
| Novartis | 12 | $176 |
| Gilead | 8 | $135 |
| Amgen | 8 | $120 |
| Dexcom, Inc. | 7 | $113 |
| Teva Pharmaceuticals USA, Inc. | 6 | $85 |
| Abbott | 5 | $77 |
| Welch Allyn | 1 | $63 |
| Sanofi Pasteur Inc. | 3 | $45 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $41 |
| Aimmune Therapeutics, Inc. | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $22 |
| Sobi, Inc | 1 | $19 |
| Insulet Corporation | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ANORO$124
How this compares
$2,767 in reported general payments places this provider in the 75th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 93 | $140,537 |
| OzempicSemaglutide | 76 | $121,297 |
| TradjentaLinagliptin | 81 | $110,397 |
| TrulicityDulaglutide | 90 | $89,691 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $73,437 |
| Spiriva RespimatTiotropium Bromide | 59 | $70,650 |
| EliquisApixaban | 37 | $43,543 |
| FarxigaDapagliflozin Propanediol | 30 | $39,283 |
| VraylarCariprazine Hcl | 16 | $34,454 |
| EntrestoSacubitril/Valsartan | 14 | $28,021 |
| CreonLipase/Protease/Amylase | 14 | $23,208 |
| JanuviaSitagliptin Phosphate | 24 | $21,617 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 20 | $17,785 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $17,422 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $14,159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Combivent Respimat | $182 | $339,369253 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $308 | $97,92781 claims |
| Lilly USA, LLCTrulicity | $213 | $89,69190 claims |
| AbbVieVraylar, Creon | $401 | $57,66230 claims |
| NovartisEntresto | $176 | $28,02114 claims |
| MerckJanuvia | $183 | $21,61724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Elkhart
- Vikram MehtaElkhart$24K
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.